Sprintec

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sprintec

Quick Facts about Sprintec

Property Description
Active ingredient Ethinyl Estradiol, Norgestimate
Form Oral tablet
Pharmacological class Combination hormonal contraceptive
Common use Birth control (Contraception)
Origin Synthetic steroid hormones

What Type of Medicine is Sprintec?

Sprintec is defined as a combination hormonal contraceptive, which serves as a prescription-only medication for birth control. This medicine belongs to the pharmacological class of Contraceptives and is a common generic variant of the original combination, providing contraception to females of reproductive potential. As an oral contraceptive tablet, Sprintec is part of the broader category of combined hormonal agents used to regulate the reproductive cycle.


Composition and Form: Ethinyl Estradiol and Norgestimate

The therapeutic profile of Sprintec is established by its two active ingredients: the estrogen compound Ethinyl Estradiol and the progestin compound Norgestimate. Both compounds are synthetic steroid hormones, distinguishing the product as a combination product that delivers two different hormonal components. The inclusion of Norgestimate classifies it as a third-generation progestin within this class of medication, a composition used in various versions including Ortho-Cyclen and Previfem. Sprintec is supplied as a monophasic formulation, meaning all active tablets contain a fixed, uniform amount of both hormones throughout the active dosing period. The medicine is administered via the oral route in the form of a tablet.


How Sprintec Provides Contraception (General Purpose)

The general purpose of taking this medication is to prevent pregnancy by systematically interrupting the complex biological requirements for conception. Sprintec achieves contraception through the combined actions of its hormones, primarily by suppressing the pituitary signals that trigger ovulation (the release of an egg), altering the consistency of cervical fluid to restrict sperm movement, and modifying the uterine lining. This collective mechanism makes the drug an effective method of birth control for women seeking a contraceptive option.

Regulatory References

  1. U.S. Food and Drug Administration

What side effects are possible with Sprintec?

Possible side effects and safety information

The safety profile of this combination hormonal contraceptive is established by regulatory documentation, which classifies possible side effects based on their frequency and the body systems affected. These official classifications organize the risks associated with the medicine.

Adverse Reactions by Frequency

Adverse reactions that are frequently observed in regulatory studies are typically categorized as Very Common or Common events. Reactions commonly listed in official documentation include headaches, nausea, vomiting, and breast tenderness. These effects are often related to the initial cycles of use, such as breakthrough bleeding or spotting, which is an expected pattern of exposure to the medication.

Serious Adverse Reactions

The official labeling highlights a specific category of Serious Adverse Reactions (SARs) that are rare but clinically significant. The primary safety concerns documented include the risk of Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), including stroke and myocardial infarction. Other serious events described in regulatory texts involve the potential for developing hepatic neoplasia (liver tumors) and significant hypertension.

Population-Specific Safety Constraints

Specific limitations on use are mandated in the official safety text for certain groups. The medication is officially contraindicated in females over the age of 35 who smoke, due to a substantially increased risk of serious cardiovascular events. Safety constraints also apply to individuals with a history of thromboembolic disorders or certain pre-existing conditions, such as severe hepatic disease or known estrogen-sensitive cancers.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Sprintec (Norgestimate and Ethinyl Estradiol) addresses the potential for acute overdosage based on documented clinical experience. Information provided by governmental health authorities indicates that acute ingestion of large doses of this combination hormonal contraceptive is generally not expected to result in severe or life-threatening outcomes.

Feature Official Regulatory Statement
Documented Manifestations Nausea, vomiting, and withdrawal bleeding (may occur in females).
Acute Severity No serious ill effects reported from acute ingestion.
Mandated Treatment Treatment should be symptomatic.
Antidote Status No specific antidote is listed or required.

Regulatory documentation classifies the severity as low, noting that no serious problems have been reported even when the medication has been accidentally ingested in large amounts by young children. Due to this low acute toxicity profile, the primary focus of emergency response is managing the reported manifestations.

When an overdose is suspected, medical attention is required to initiate symptomatic treatment to address documented signs such as nausea, vomiting, or persistent bleeding. This supportive care is the explicit management measure documented in the official prescribing information, as there is no specific antidote available for the hormonal compounds. All cases of suspected overdosage should prompt contact with emergency medical services or a poison control center for appropriate guidance.

Therapeutic Uses of Sprintec

The primary therapeutic role of Sprintec (Ethinyl Estradiol/Norgestimate) extends beyond its core function of preventing unintended pregnancy to encompass the relief and management of specific chronic conditions and symptomatic patterns that may affect daily stability.

This therapeutic profile is used for effective contraception for women of reproductive potential. The medicine is primarily applied in situations involving reproductive health management, attenuation of symptoms related to physical discomfort, and management of hormonally-driven skin conditions.

The key benefits generally relate to supportive contraception, support for managing menstrual cycle predictability, support for managing severe menstrual pain (dysmenorrhea), assists with managing excessive blood loss (menorrhagia), and the management of moderate acne vulgaris. This medication provides supportive management for symptoms and generally contributes to improved day-to-day comfort and planning ability during the monthly cycle.


Quick Fact: Relief for Recurrent Symptom Domains

Symptom Domain General Benefit
Menstrual Pain/Cramping (Dysmenorrhea) Helps maintain a sense of stability and comfort during symptomatic phases.
Excessive Blood Loss (Menorrhagia) Supports the patient during episodes of heightened discomfort by easing distress.
Hormonal Breakouts (Moderate Acne) May assist with addressing concerns related to skin appearance and supporting general well-being.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sprintec — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Females of reproductive potential seeking contraception.

Populations for whom use is not recommended (if applicable):

  • Lactating women (breastfeeding women).

Populations for whom use is contraindicated:

  • Women over 35 years old who smoke cigarettes.
  • Individuals with a high risk of arterial or venous thrombotic diseases, including a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, or Myocardial Infarction.
  • Patients with known or suspected breast cancer, liver tumors, or acute/chronic liver disease with abnormal function.
  • Patients with uncontrolled hypertension, diabetes mellitus with vascular disease, or migraine headaches with aura.
  • Women who are pregnant or have undiagnosed abnormal uterine bleeding.

Age-related eligibility rules:

  • Use is not indicated for females before menarche (onset of menstruation) or for postmenopausal women.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated; Not Recommended; Not Indicated.

Regulatory basis (EMA / FDA / etc.): U.S. Food and Drug Administration (FDA) Prescribing Information (Labeling).

Resulting eligibility structure

Official eligibility statements:

  • Use is Contraindicated in populations with a high risk of vascular disease and certain hormone-sensitive cancers.
  • The medicine is Not Recommended during lactation and Not Indicated for pre-menarche or postmenopausal age groups.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents strictly define the population eligibility for Sprintec by establishing multiple absolute prohibitions centered on significant health risks, primarily thromboembolic events and hormone-sensitive conditions. This regulatory structure dictates that use is limited to females of reproductive potential who do not meet any of the non-eligibility criteria, such as a combination of smoking and age over 35, or pre-existing severe cardiovascular or liver disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Sprintec (Ethinyl Estradiol/Norgestimate) is predominantly governed by the way co-administered substances affect the plasma exposure of the contraceptive hormones. This information is based strictly on regulatory documents, defining specific restrictions and required administrative conditions.


Official Contraindications and Restrictions

Co-administration is contraindicated with specific Hepatitis C combination drug regimens containing Ombitasvir, Paritaprevir, and Ritonavir, with or without Dasabuvir, as documented in the regulatory label. The use of the herbal product St. John's Wort is restricted due to its strong potential to induce metabolism, leading to a loss of contraceptive protection.


Pharmacokinetic and Exposure Interactions

Many interactions are pharmacokinetic in nature, primarily through effects on the CYP3A4 enzyme system:

  • Enzyme Inducers (e.g., Carbamazepine, Phenytoin, Rifampicin, Topiramate) may decrease the plasma concentrations of Ethinyl Estradiol and the active progestin metabolite, which may result in a loss of contraceptive efficacy.
  • Enzyme Inhibitors (e.g., Azole antifungals, Grapefruit Juice) may increase the plasma concentration of Ethinyl Estradiol.

Furthermore, the oral contraceptive is officially documented to decrease the plasma concentrations of Lamotrigine. To prevent reduced exposure of the contraceptive components by Colesevelam, regulatory labeling specifies that the two products must be administered 4 hours apart.

Mechanism of Action

Sprintec is a combination hormonal product containing the progestin norgestimate (a prodrug metabolized to norelgestromin and norgestrel) and the estrogen ethinyl estradiol. The primary mechanism of action involves modulation of the hypothalamic-pituitary-ovarian axis (HPO axis).

  • Norelgestromin acts as an agonist at the progesterone receptor, primarily in the hypothalamus and pituitary gland.
  • Ethinyl estradiol acts as an agonist at the estrogen receptor in the same tissues.

This combined negative feedback suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, leading to a downstream decrease in the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. This cascade prevents the dominant ovarian follicle from maturing fully and attaining the LH surge threshold, resulting in the inhibition of ovulation.

Secondary actions include norelgestromin-mediated alterations to the cervical mucus, increasing its viscosity, and modification of the endometrium, making it less receptive to cellular adhesion. Ethinyl estradiol also increases the synthesis of Sex Hormone-Binding Globulin (SHBG) in the liver, which modulates the systemic concentration of free androgens.

Dosage and Administration Information

How to Use Sprintec

The usage of Sprintec (norgestimate and ethinyl estradiol) is governed by a fixed, 28-day cyclic protocol for daily oral administration. This approach is standardized to ensure continuous hormonal delivery.


Administration Scope

Instruction Domain Official Guideline
Route of Administration The medicine is taken orally (swallowed by mouth).
Dosing Schedule One tablet daily for 28 consecutive days, following the sequence: 21 days of active (hormonal) tablets, followed by 7 days of inactive (placebo) tablets.
Timing in relation to meals May be administered without regard to meals (with or without food).
Frequency and Timing Administration is once daily and must occur at the same time every day to maintain consistent hormonal levels.

Procedural and Population Constraints

The use protocol requires strict adherence to a sequential schedule and is subject to specific timing rules, particularly when initiating the treatment or managing administration lapses.

Instruction Domain Official Guideline
Starting Regimens The first pack must be started using either the Day 1 Start or the Sunday Start method.
Post-Partum Use Initiation is typically advised not to occur until four weeks after childbirth or a second-trimester termination. Conversely, use may be started immediately following a first-trimester abortion.
Missed Dose Protocol Specific instructions are provided for managing missed active tablets, which may necessitate the temporary use of back-up contraception depending on the number and timing of the missed tablets.
Order of Tablets The tablets must be taken in the exact order directed by the sequence printed on the blister pack, advancing immediately to the next pack after the inactive tablets are completed.

Recent Clinical Evidence

Research Evidence Overview

Sprintec is a combination oral contraceptive containing the progestin norgestimate and the estrogen ethinyl estradiol. Its clinical profile has been established through several trials and long-term observational data focusing on its indicated uses: pregnancy prevention and the treatment of moderate acne vulgaris.


Contraceptive Efficacy

Clinical trials have evaluated the effectiveness of norgestimate and ethinyl estradiol in preventing pregnancy. When used consistently and correctly, this type of combined oral contraceptive exhibits high contraceptive reliability. A major mechanism observed is the suppression of ovulation, complemented by changes to cervical mucus and the uterine lining, which collectively reduce the likelihood of fertilization and implantation.


Efficacy in Treating Moderate Acne

Clinical research has also investigated the use of this formulation in improving skin conditions. In two six-month, randomized, double-blind, placebo-controlled trials, the formulation was evaluated in females aged 15 to 49 with moderate acne. The active treatment group showed a statistically greater reduction in both inflammatory lesion counts and total lesion counts compared to the placebo group. The improvement recorded by investigators in the active group was notably higher than in the placebo group.


Long-Term Safety and Tolerability

Safety and tolerability have been studied across various age groups. While common side effects such as headache, nausea, and breakthrough bleeding were reported, these generally decrease after the first few cycles. Post-marketing surveillance and long-term data emphasize that, like all combined hormonal contraceptives, use is associated with an increased risk of serious cardiovascular events, including thromboembolism (blood clots), especially in individuals with pre-existing risk factors.

Key Studies & References

  1. Sprintec (Norgestimate and Ethinyl Estradiol Tablets, USP) official prescribing information (Package Insert/Label)
  2. A combined oral contraceptive containing norgestimate and ethinyl estradiol for the treatment of moderate acne vulgaris: a review of the clinical data

Frequently Asked Questions (FAQ)

Common questions about Sprintec (FAQ)


Q: Does Sprintec help with acne, or is it only for preventing pregnancy?

A: The official product labeling describes two indications for this medicine: the prevention of pregnancy (contraception) and the treatment of moderate acne vulgaris in females who desire to use an oral contraceptive.


Q: What are the most common side effects people report when starting Sprintec?

A: The most common adverse reactions listed in the official labeling include headache, nausea, vomiting, breast tenderness or pain, and abdominal discomfort. Irregular bleeding, such as spotting or breakthrough bleeding, is also frequently reported.


Q: How long does it take for side effects from Sprintec to go away?

A: Studies and official information indicate that many common side effects, especially irregular bleeding and nausea, are often associated with the initial cycles of use. These effects may decrease or resolve after the first few months as the body adjusts to the medicine.


Q: Is it common to have nausea when first taking Sprintec?

A: Yes, nausea is a very common adverse reaction listed in the official patient information. It is noted that this symptom is especially common during the initial period that a person takes the medicine, such as the first few months.


Q: Is it normal to have spotting during the first few months on Sprintec?

A: Irregular bleeding or spotting between periods is a common and expected side effect, particularly during the first few months of use. This is listed in the official safety information as a frequent pattern of adjustment to the medication.


Q: If I have a vomiting or diarrhea episode, does it affect the effectiveness of Sprintec?

A: Official dosage instructions state that vomiting or severe diarrhea that occurs within three to four hours after taking an active tablet may prevent the medicine from being fully absorbed. If this happens, it is necessary to follow the guidance for a missed dose.


Q: Can taking ibuprofen or acetaminophen affect how Sprintec works?

A: Regulatory information notes a minor interaction with acetaminophen, where the oral contraceptive may decrease the effects of the pain reliever. Official labeling generally does not highlight a significant interaction with common pain relievers like ibuprofen with typical therapeutic dosages.


Q: What is the general duration of use described for Sprintec?

A: Sprintec is an oral contraceptive regimen intended for continuous daily use in 28-day cycles. For the purpose of contraception, the medicine is intended to be used for as long as a person desires pregnancy prevention.


Q: Does the package insert for Sprintec mention any effects on future fertility?

A: The mechanism of action for this medication is entirely reversible, as the effects on the body's natural hormones are not permanent. The regulatory data notes that the risk of blood clotting associated with the medicine gradually disappears after use is discontinued.


Q: Can Sprintec affect the results of blood tests?

A: Yes, the official labeling advises that this medicine may affect the results of certain laboratory tests. These tests may include those related to liver function, the body’s clotting ability (coagulation), and thyroid function.


Q: How does Sprintec compare to generic versions in terms of active ingredients?

A: Sprintec is a generic product. All generic versions of the original brand-name drug are required by the FDA to contain the identical active ingredients (norgestimate and ethinyl estradiol) in the same strength and dosage form to ensure bioequivalence (meaning they work the same way in the body).


Q: Is it true that Sprintec can cause weight gain?

A: Changes in weight are included in the list of possible adverse reactions found in the official prescribing information for the medicine.


Q: How quickly does Sprintec start working to prevent pregnancy?

A: Official instructions for the Sunday Start regimen require the use of an additional non-hormonal, or back-up, method of contraception for the first seven days. This waiting period suggests that full contraceptive efficacy is established after that initial period of continuous active tablet intake.


Q: Will Sprintec make my periods lighter or shorter?

A: Official product information focuses on regulating the menstrual cycle and generally does not make explicit claims regarding whether periods will become lighter or shorter. While a change in the characteristics of the monthly withdrawal bleed may be experienced, the effect varies between individuals.


Q: Does Sprintec contain the same hormones as Lo Loestrin Fe?

A: No. While both medicines contain the estrogen component, Ethinyl Estradiol, the progestin components are different. Sprintec contains Norgestimate, while Lo Loestrin Fe contains Norethindrone acetate.


Q: Does long-term use of Sprintec increase any health risks?

A: Official labeling includes information from studies that examine the long-term use of combined oral contraceptives, which note potential risks associated with prolonged use. The regulatory documents emphasize the importance of continuous monitoring and risk assessment over time.


Q: Can Sprintec affect my mood or cause anxiety?

A: Mood changes, including depression and nervousness, and anxiety are included in the list of adverse reactions reported in association with the use of the medicine, according to official documentation.


Q: Do official documents mention any effects of Sprintec on libido?

A: Decreased libido (sex drive) is listed as a reported adverse reaction of the medicine in official documentation.


Q: Is Sprintec associated with changes in vision or wearing contact lenses?

A: Yes, adverse reaction reports mention the possibility of changes in vision and difficulties with contact lenses (intolerance) for users of the medicine.


Q: Can Sprintec affect the appearance of skin or hair?

A: The official labeling mentions the possibility of developing blotchy, dark areas on the skin called melasma. Changes in hair growth, including hair loss or increased growth, have also been reported as adverse reactions.


Q: Is it possible for Sprintec to cause high blood pressure?

A: An increase in blood pressure has been reported in women taking the medicine. The labeling advises that monitoring of blood pressure is necessary and notes that the medicine should be discontinued if the pressure rises significantly.


Q: Do doctors recommend a break from Sprintec after a certain time?

A: The official daily dosing schedule requires continuous administration in the 28-day cycle for the purpose of contraception. Planned breaks from the active tablet regimen are not part of the labeled protocol.


Q: Why is it important to disclose all health conditions when getting a prescription for Sprintec?

A: Disclosing all health conditions is necessary because the official warnings and eligibility criteria are based on the risk of serious cardiovascular events. This risk is higher in people with certain pre-existing conditions, such as uncontrolled high blood pressure or a history of blood clots.


Q: Are there any restrictions on who can use Sprintec based on age or body mass index (BMI)?

A: The official prescribing information states that use in females over the age of 35 who smoke is absolutely contraindicated. The labeling also notes that certain conditions, such as morbid obesity, are considered risk factors for serious cardiovascular events, which may be compounded by the use of this medicine.

How should Sprintec be stored and disposed of?

How to Store and Dispose of Sprintec

This section outlines the mandatory storage and disposal protocols for Sprintec, according to official regulatory documentation.

Storage Conditions

Sprintec must be stored at 25 C (77 F), which is defined as Controlled Room Temperature. The medication is stable and effective when exposed to temperature excursions only between 15 C and 30 C (59 F and 86 F). The product must be kept in its original blister pack tablet dispenser and always stored out of the sight and reach of children.

Disposal Instructions

Sprintec is not on the list of medicines recommended for disposal by flushing down the sink or toilet. If a drug take-back program is unavailable, unused or expired tablets should be removed from their original containers, mixed with an undesirable substance (such as used coffee grounds or dirt), and placed into a sealed bag or container before disposal in the household trash. All identifying information on the prescription label must be scratched out before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sprintec found in:

A-Z Index: